Institution
Kyungpook National University Hospital
Healthcare•Daegu, South Korea•
About: Kyungpook National University Hospital is a healthcare organization based out in Daegu, South Korea. It is known for research contribution in the topics: Transplantation & Medicine. The organization has 2255 authors who have published 3201 publications receiving 58466 citations.
Topics: Transplantation, Medicine, Myocardial infarction, Cancer, Population
Papers published on a yearly basis
Papers
More filters
••
National Taiwan University1, Anhui Medical University2, Korea University3, Fudan University4, Memorial Hospital of South Bend5, Academy of Military Medical Sciences6, Third Military Medical University7, Dalian Medical University8, Kyungpook National University Hospital9, Sir Run Run Shaw Hospital10, Bayer HealthCare Pharmaceuticals11, Bayer Corporation12, Sun Yat-sen University13
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Abstract: Summary Background Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and safety of new therapeutic options in an Asia-Pacific population is thus important. We did a multinational phase III, randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of sorafenib in patients from the Asia-Pacific region with advanced (unresectable or metastatic) hepatocellular carcinoma. Methods Between Sept 20, 2005, and Jan 31, 2007, patients with hepatocellular carcinoma who had not received previous systemic therapy and had Child-Pugh liver function class A, were randomly assigned to receive either oral sorafenib (400 mg) or placebo twice daily in 6-week cycles, with efficacy measured at the end of each 6-week period. Eligible patients were stratified by the presence or absence of macroscopic vascular invasion or extrahepatic spread (or both), Eastern Cooperative Oncology Group performance status, and geographical region. Randomisation was done centrally and in a 2:1 ratio by means of an interactive voice-response system. There was no predefined primary endpoint; overall survival, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), and safety were assessed. Efficacy analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00492752. Findings 271 patients from 23 centres in China, South Korea, and Taiwan were enrolled in the study. Of these, 226 patients were randomly assigned to the experimental group (n=150) or to the placebo group (n=76). Median overall survival was 6·5 months (95% CI 5·56–7·56) in patients treated with sorafenib, compared with 4·2 months (3·75–5·46) in those who received placebo (hazard ratio [HR] 0·68 [95% CI 0·50–0·93]; p=0·014). Median TTP was 2·8 months (2·63–3·58) in the sorafenib group compared with 1·4 months (1·35–1·55) in the placebo group (HR 0·57 [0·42–0·79]; p=0·0005). The most frequently reported grade 3/4 drug-related adverse events in the 149 assessable patients treated with sorafenib were hand-foot skin reaction (HFSR; 16 patients [10·7%]), diarrhoea (nine patients [6·0%]), and fatigue (five patients [3·4%]). The most common adverse events resulting in dose reductions were HFSR (17 patients [11·4%]) and diarrhoea (11 patients [7·4%]); these adverse events rarely led to discontinuation. Interpretation Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated. Taken together with data from the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol (SHARP) trial, sorafenib seems to be an appropriate option for the treatment of advanced hepatocellular carcinoma. Funding Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
4,890 citations
••
Samsung Medical Center1, University of Ulsan2, Ewha Womans University3, Ajou University4, New Generation University College5, Korea University6, Soonchunhyang University7, Konkuk University8, Hanyang University9, Sungkyunkwan University10, Wonkwang University11, Catholic University of Korea12, Inje University13, Yonsei University14, Kyungpook National University Hospital15, Dong-a University16, St Mary's Hospital17
TL;DR: The Task Force on Thyroid Nodules of the KSThR has revised the recommendations for the ultrasound diagnosis and imaging-based management of thyroid nodules, based on a comprehensive analysis of the current literature and the consensus of experts.
Abstract: The rate of detection of thyroid nodules and carcinomas has increased with the widespread use of ultrasonography (US), which is the mainstay for the detection and risk stratification of thyroid nodules as well as for providing guidance for their biopsy and nonsurgical treatment. The Korean Society of Thyroid Radiology (KSThR) published their first recommendations for the US-based diagnosis and management of thyroid nodules in 2011. These recommendations have been used as the standard guidelines for the past several years in Korea. Lately, the application of US has been further emphasized for the personalized management of patients with thyroid nodules. The Task Force on Thyroid Nodules of the KSThR has revised the recommendations for the ultrasound diagnosis and imaging-based management of thyroid nodules. The review and recommendations in this report have been based on a comprehensive analysis of the current literature and the consensus of experts.
634 citations
••
University of Pavia1, Shiga University2, Kyungpook National University Hospital3, St George's, University of London4, Children's National Medical Center5, Leiden University Medical Center6, University of Barcelona7, University of Oulu8, Monroe Carell Jr. Children's Hospital at Vanderbilt9, University of British Columbia10, University of Rochester Medical Center11, Nippon Medical School12, Johns Hopkins University13, Washington University in St. Louis14
TL;DR: This international consensus statement is the collaborative effort of three medical societies representing electrophysiology in North America, Europe, and Asian-Pacific area and summarizes the opinion of the international writing group members based on their own experience and on a general review of the literature.
Abstract: This international consensus statement is the collaborative effort of three medical societies representing electrophysiology in North America, Europe, and Asian-Pacific area: the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), and the Asia Pacific Heart Rhythm Society. The objective of the consensus document is to provide clinical guidance for diagnosis, risk stratification, and management of patients affected by inherited primary arrhythmia syndromes. It summarizes the opinion of the international writing group members based on their own experience and on a general review of the literature with respect to the clinical data on patients affected by channelopathies.
This document does not address the indications of genetic testing in patients affected by inherited arrhythmias and their family members. Diagnostic, prognostic, and therapeutic implications of the results of genetic testing are also not included in this document because this topic has been covered by a recent publication1 coauthored by some of the contributors of this consensus document, and it remains the reference text on this topic. Guidance for the evaluation of patients with idiopathic ventricular fibrillation, sudden arrhythmic death …
555 citations
••
TL;DR: A better understanding of this complex syndrome may obviate unnecessary investigations and allow management of the associated problems in prompt and appropriate ways.
523 citations
••
Icahn School of Medicine at Mount Sinai1, University of Barcelona2, French Institute of Health and Medical Research3, Institut Gustave Roussy4, Kindai University5, Asan Medical Center6, Samsung Medical Center7, Kyungpook National University Hospital8, Chang Gung University9, Taipei Veterans General Hospital10, University of Hong Kong11, Toronto General Hospital12, University of California, Los Angeles13, Bristol-Myers Squibb14
TL;DR: In patients with HCC who had been treated with sorafenib, brivanib did not significantly improve OS, and the observed benefit in the secondary outcomes of TTP and ORR warrants further investigation.
Abstract: Purpose Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, double-blind, randomized, placebo-controlled trial assessed brivanib in patients with HCC who had been treated with sorafenib. Patients and Methods In all, 395 patients with advanced HCC who progressed on/after or were intolerant to sorafenib were randomly assigned (2:1) to receive brivanib 800 mg orally once per day plus best supportive care (BSC) or placebo plus BSC. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), and disease control rate based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and safety. Results Median OS was 9.4 months for brivanib and 8.2 mont...
521 citations
Authors
Showing all 2294 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jongmin Lee | 150 | 2257 | 134772 |
Robert A. Kyle | 146 | 1221 | 89997 |
S. Vincent Rajkumar | 120 | 830 | 61519 |
Angela Dispenzieri | 117 | 1107 | 60367 |
Morie A. Gertz | 115 | 1162 | 56442 |
Shaji Kumar | 111 | 1265 | 53237 |
Jordi Bruix | 106 | 440 | 77318 |
Philip R. Greipp | 93 | 302 | 35805 |
Rafael Fonseca | 92 | 415 | 36177 |
Martha Q. Lacy | 87 | 713 | 25974 |
James J. Yoo | 81 | 491 | 27738 |
John A. Lust | 79 | 395 | 25899 |
Inkyu Lee | 74 | 965 | 25712 |
Suzanne R. Hayman | 71 | 476 | 19322 |
Vikas Gupta | 63 | 455 | 17632 |